| Z04019 | |
|
|
|
| ¥48,938.00 | |
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized CD5 hFc Chimera, Avi, Human at 1μg/ml (100μl/well) on the plate can bind Biotinylated Anti-CD5 Antibody, hFc Tag. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 67.1 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 75-82 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS，(pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | CD5: a type I transmembrane protein found on T cells, thymocytes, and some B cells that is a ligand for CD72 and is involved in cellular activation or adhesion; expressed in B-cell chronic lymphocytic leukemia and T-cell lymphoma. |
| Synonyms | CD5 molecule; CD5; LEU1; T1; CD5 antigen |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
